

13 August 2023

**Justification of Missing Clinical Results for Study BL-8040.AML.202 (BATTLE)**


**EudraCT Number:** 2017-002237-29  
**Sponsor Protocol Number:** BL-8040.AML.202  
**Start Date:** 2017-12-06

To whom it may concern,

Clinical study BL-8040.AML.202 (EudraCT 2017-002237-29) screened 22 subjects globally. During a period of more than 18 months, only one patient was enrolled (in the Czech Republic) despite recruitment efforts by 21 sites in 7 countries. As such, the clinical trial was prematurely terminated in all sites due to difficulties in recruitment of eligible patients and no results are available.

Sincerely,

**DocuSigned by:**

A blue ink signature of Jael Birenberg is enclosed within a blue DocuSigned signature box. The signature is written in a cursive, handwritten style.

EAD6BBC0333B41D...

Jael Birenberg, MSc

Senior Director, Head of Regulatory Affairs, Quality Assurance and Pharmacovigilance

BioLineRx Ltd.

[jaelb@biolinerx.com](mailto:jaelb@biolinerx.com)

Phone: +972-8-6429125

Mobile: +972-54-8886713

Cc

Dr Dorothy Bray, ImmunoClin Limited, European Legal Representative for the clinical research,  
[dorothy.bray@immunoclin.com](mailto:dorothy.bray@immunoclin.com)